Volume 10 Supplement 1

Proceedings of the WSCTS 25th Anniversary Congress

Open Access

Acute fulminating massive pulmonary embolism treated with aggressive endovascular or surgical approach And ECMO

  • Shih-Chen Tsai1,
  • Jung-Ming Yu1,
  • Su-Chin Tsao2,
  • Ying-Che Sun2,
  • Yi-Liang Wu2,
  • An-Hua Sun2 and
  • Tsung-Po Tsai2
Journal of Cardiothoracic Surgery201510(Suppl 1):A217

https://doi.org/10.1186/1749-8090-10-S1-A217

Published: 16 December 2015

Aims/Objectives

Massive pulmonary embolism (PE) is frequent lethal, but rapid diagnosis and aggressive therapy with endovascular or surgical thromboembolectomy and extracorporeal membrane oxygenation (ECMO) may be lifesaving. We reviewed our current cases to find that whether the aggressive surgical approaches is the best alternative or not.

Method

Five female patients (age 23, 37, 58, 70 and 76, mean 52.8) were diagnosed as massive pulmonary embolism with either acute irreversible pulmonary failure or cardiac collapse (2 CPR) by Chest CT or pulmonary angiography. All patients required ECMO support in addition to 2 endovascular Angiojet aspiration or 1 surgical pulmonary thromboembolectomy. The duration for ECMO survivors were 1, 2 and 7 days, respectively. All patients required anticoagulation (3 heparin, 2 r-TPA, 3 Coumadin and 1 urokinase) to resolve the residual emboli.

Results

One died from ECMO cannula insertion complication of massive retroperitoneal hematoma and bleeding and the other one died of multiorgan failure (MOF). Three were weaned from ECMO and was discharged in good condition at follow-up.

Discussion/Conclusion

Aggressive endovascular or surgical pulmonary thromboembolectomy in combination with ECMO appears to have beneficial effects for massive pulmonary embolism with acute cardiopulmonary failure.

Authors’ Affiliations

(1)
Department of Medical Education, Cathay General Hospital
(2)
Division of Cardiovascular Surgery, Chung Shan Medical University Hospital

Copyright

© Tsai et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement